Suppr超能文献

上皮样肉瘤中SMARCB1/INI1基因改变罕见:鉴别上皮样肉瘤与恶性横纹肌样瘤的有用工具。

Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.

作者信息

Kohashi Kenichi, Izumi Teiyu, Oda Yoshinao, Yamamoto Hidetaka, Tamiya Sadafumi, Taguchi Tomoaki, Iwamoto Yukihide, Hasegawa Tadashi, Tsuneyoshi Masazumi

机构信息

Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

出版信息

Hum Pathol. 2009 Mar;40(3):349-55. doi: 10.1016/j.humpath.2008.08.007. Epub 2008 Oct 29.

Abstract

Loss of SMARCB1/INI1 protein expression is considered useful for confirming a histologic diagnosis of malignant rhabdoid tumor. However, loss of SMARCB1/INI1 protein expression has recently been reported in other tumors as well, including a few cases of epithelioid sarcoma. In addition, the histopathologic differences between proximal-type epithelioid sarcoma and malignant rhabdoid tumor have not been conclusively defined. We analyzed SMARCB1/INI1 protein expression in 54 epithelioid sarcoma (proximal-type, 25; distal-type, 29) and examined alterations of the SMARCB1/INI1 gene in the cases lacking protein expression. We found that 19 (76.0%) proximal-type epithelioid sarcoma and 27 (93.1%) distal-type epithelioid sarcoma showed loss of SMARCB1/INI1 protein expression. Analysis of 39 cases with loss of protein expression revealed 4 cases (10.3%) with SMARCB1/INI1 gene alterations at the DNA level (homozygous deletion, 2; 1- or 2-bp deletion, 2) that could have induced the loss of gene products, and all 4 of these were proximal-type epithelioid sarcoma. Epithelioid sarcoma was thus associated with a high frequency of loss of SMARCB1/INI1 protein expression similar to that in malignant rhabdoid tumor. However, the frequency of SMARCB1/INI1 gene alteration at the DNA level in proximal-type epithelioid sarcoma was significantly lower than that in malignant rhabdoid tumor. In addition, the prognosis of patients with malignant rhabdoid tumor is significantly worse than that of patients with proximal-type epithelioid sarcoma (P = .001). Therefore, proximal-type epithelioid sarcoma and malignant rhabdoid tumor are suggested to be distinctive tumors with respect to the mechanism of the loss of SMARCB1/INI1 protein expression. Analysis of alterations in the SMARCB1/INI1 gene may thus be a useful diagnostic tool to distinguish proximal-type epithelioid sarcoma from malignant rhabdoid tumor.

摘要

SMARCB1/INI1蛋白表达缺失被认为有助于确诊恶性横纹肌样瘤的组织学诊断。然而,最近也有报道称SMARCB1/INI1蛋白表达缺失在其他肿瘤中也存在,包括少数上皮样肉瘤病例。此外,近端型上皮样肉瘤与恶性横纹肌样瘤之间的组织病理学差异尚未明确界定。我们分析了54例上皮样肉瘤(近端型25例,远端型29例)中SMARCB1/INI1蛋白的表达情况,并检测了蛋白表达缺失病例中SMARCB1/INI1基因的改变。我们发现,19例(76.0%)近端型上皮样肉瘤和27例(93.1%)远端型上皮样肉瘤存在SMARCB1/INI1蛋白表达缺失。对39例蛋白表达缺失病例的分析显示,有4例(10.3%)在DNA水平存在SMARCB1/INI1基因改变(纯合缺失2例,1或2个碱基对缺失2例),这可能导致基因产物缺失,且这4例均为近端型上皮样肉瘤。因此,上皮样肉瘤与恶性横纹肌样瘤一样,SMARCB1/INI1蛋白表达缺失的频率较高。然而,近端型上皮样肉瘤中DNA水平的SMARCB1/INI1基因改变频率显著低于恶性横纹肌样瘤。此外,恶性横纹肌样瘤患者的预后明显差于近端型上皮样肉瘤患者(P = 0.001)。因此,近端型上皮样肉瘤和恶性横纹肌样瘤在SMARCB1/INI1蛋白表达缺失机制方面可能是不同的肿瘤。因此,分析SMARCB1/INI1基因的改变可能是区分近端型上皮样肉瘤与恶性横纹肌样瘤的有用诊断工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验